TNF and myeloid sarcoma: While these findings suggest an involvement for TNFα in the pathogenesis of MS, treatment with monoclonal neutralizing anti-TNFα antibodies as well as neutralizing soluble receptors has, paradoxically, resulted in MS disease exacerbation [55,56].